-+ 0.00%
-+ 0.00%
-+ 0.00%

KDventures' Modus Therapeutics malaria trial identifies sevuparin dose for children

PUBT·10/21/2026 10:02:20
Listen to the news
KDventures' Modus Therapeutics malaria trial identifies sevuparin dose for children
  • KDventures announced October 21, 2026, that portfolio company Modus Therapeutics' Phase Ib SEVUSMART results were published in Nature Communications.
  • The trial evaluated sevuparin as an adjunctive treatment for children with severe malaria in Kenya and Zambia.
  • Elevated coagulation markers limited dosing, but no clinical bleeding complications occurred; observed mortality was below the expected risk based on disease severity.
  • Modus Therapeutics plans to work with Professor Kathryn Maitland's team on a Phase II study to confirm the findings.
  • The investment company's stake in Modus Therapeutics is 51%; Modus holds commercial rights to sevuparin.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. KDventures AB published the original content used to generate this news brief on October 21, 2026, and is solely responsible for the information contained therein.